Search clinical trials for: Vildagliptin (Galvus)

Total 264 results

Ziv Hospital

Unknown

Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

Israel
Rio de Janeiro State University
Laboratory for Clinical and Experimental Research on Vascular Biology

Completed

Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

1- Microvascular Function | 2-oxidative Stress | 3-inflammation

Brazil
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

Diabetes Mellitus, Type 2

Germany, Switzerland
University Hospital, Strasbourg, France
Novartis

Completed

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Haemodialyzed, Type 2 Diabetes

France
Korea University Anam Hospital

Unknown

Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes

Diabetes Mellitus | Oxidative Stress

Korea, Republic of
Pusan National University Hospital

Completed

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of
Peking University

Unknown

Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients (VISA-T2DM)

Obesity | Diabetes Mellitus, Type 2

China
Sanofi

Completed

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Russian Federation
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST)

Type 2 Diabetes Mellitus

Egypt, United Kingdom, Turkey, Lebanon, Russian Federation, Tunisia, Malaysia, Germany, Spain, Saudi Arabia, Denmark, Indonesia, Jordan, Kuwait, Singapore, United Arab Emirates
Royal Devon and Exeter NHS Foundation Trust
Novartis Pharmaceuticals; National Institute for Health Research, United Kingdom

Completed

The Vascular Effects of Vildagliptin in Insulin Resistant Individuals

Insulin Resistance | Microvascular Disease

United Kingdom
University Hospital, Toulouse
Novartis Pharmaceuticals; Institute of Molecular Medicine of Rangueil (I2MR); Faculty of Medicine, Toulouse

Completed

Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy (DPPNAC)

Diabetes Mellitus

France
Yaounde Central Hospital
University of Yaounde 1; University of Buea

Completed

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes (LIRAVIS)

Type 2 Diabetes Mellitus

Cameroon
Hospital de Clinicas de Porto Alegre

Unknown

Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes (DIABEX-VILDA)

Diabetes Mellitus, Type 2 | Exercise | Hypoglycemic Agents | Diabetic Blood Glucose Monitoring

Brazil
Novartis

Terminated

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Johann Wolfgang Goethe University Hospital

Withdrawn

Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM). (FINNjA-DM)

SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors

Germany
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Centre Hospitalier Universitaire de Besancon
University Hospital, Strasbourg, France; Centre Hospitalier Universitaire de... and other collaborators

Recruiting

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (PRODIG)

Diabetes | Disorder Related to Renal Transplantation

France
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Diabetes Mellitus, Type 2

Spain, Argentina, Russian Federation, Norway, India, Sweden, Finland, France, Canada, Germany, Australia, Costa Rica
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Taiwan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China, Thailand, Philippines, Singapore
Lund University

Completed

Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Hypoglycemia | Diabetes

Sweden
Novartis Pharmaceuticals

Completed

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function (CGM-VISIT)

Diabetes Mellitus Type 2

Germany
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Healthy

Egypt
Handok Inc.

Completed

Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Korea, Republic of
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Federal University of São Paulo
Novartis

Unknown

Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

Type 1 Diabetes | Autoimmune Diabetes | Insulin Dependent Diabetes | Juvenile Onset Diabetes Mellitus

Brazil
Marcus Saemann

Completed

Glucose Control in Pre-Diabetic Renal Transplant Patients (GCPD)

Kidney Transplantation | Impaired Glucose Tolerance

Austria
Dr. José Fernando Vilela-Martin MD PhD
Novartis

Completed

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Hypertension | Type 2 Diabetes Mellitus | Endothelial Dysfunction

Brazil
Centro de Diabetes Curitiba Ltda

Completed

Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability (BoneGlyc)

Type 2 Diabetes Mellitus | Menopause | Osteoporosis | Osteopenia

Brazil
Novartis Pharmaceuticals

Completed

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin (ADDONIS)

Type 2 Diabetes Mellitus (T2DM)

France
Lund University

Completed

Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes

Diabetes

Sweden
Seoul National University Bundang Hospital

Completed

Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin

Diabetes

Korea, Republic of
Lund University

Completed

Vildagliptin Versus Dapagliflozin on Glucagon

Type 2 Diabetes

Sweden
Damanhour University
Tanta University

Completed

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Coronary Artery Disease | Diabetes Mellitus, Type 2

Egypt
Laboratorios Silanes S.A. de C.V.

Recruiting

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

Type 2 Diabetes

Mexico
Lin Liao

Unknown

Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
Lund University

Completed

DPP-4 Inhibition, Incretins and Islet Function (CODI24)

Type 2 Diabetes

Sweden
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Switzerland, Germany
Heidelberg University

Unknown

Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures

Heterogeneous Emphysema

Germany
Piemonti Lorenzo
Italian Diabetes Foundation

Completed

Monotherapy With Rapamycin in Long-standing Type 1 Diabetes (MONORAPA)

Diabetes Mellitus, Type 1

Italy
Novartis

Completed

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Bio-innova Co., Ltd

Not yet recruiting

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets

Healthy Subjects
Radboud University Medical Center

Completed

Vildagliptin and Endothelium-dependent Vasodilatation

Type 2 Diabetes | Endothelial Dysfunction

Netherlands
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States

3

Subscribe